Influence of Preoperative Therapy on Short- and Long-Term Outcomes of Patients with Adenocarcinoma of the Ampulla of Vater

[1]  J. Hussey,et al.  The ability of prehabilitation to influence postoperative outcome after intra-abdominal operation: A systematic review and meta-analysis. , 2016, Surgery.

[2]  J. Berlin,et al.  Potentially Curable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  Jeffrey E. Lee,et al.  Impact of hypofractionated and standard fractionated chemoradiation before pancreatoduodenectomy for pancreatic ductal adenocarcinoma , 2016, Cancer.

[4]  Jin‐Young Jang,et al.  Survival Outcomes According to Adjuvant Treatment and Prognostic Factors Including Host Immune Markers in Patients with Curatively Resected Ampulla of Vater Cancer , 2016, PloS one.

[5]  Jill O Jin,et al.  JAMA Oncology Patient Page. Performance Status in Patients With Cancer. , 2015, JAMA oncology.

[6]  Jeffrey E. Lee,et al.  Superior Mesenteric Artery Margin of Posttherapy Pancreaticoduodenectomy and Prognosis in Patients With Pancreatic Ductal Adenocarcinoma , 2015, The American journal of surgical pathology.

[7]  Kyubo Kim,et al.  Survival Benefit of Adjuvant Chemoradiotherapy in Patients With Ampulla of Vater Cancer: A Systematic Review and Meta-analysis. , 2015, Annals of surgery.

[8]  Jeffrey E. Lee,et al.  Neoadjuvant Therapy is Associated with a Reduced Lymph Node Ratio in Patients with Potentially Resectable Pancreatic Cancer , 2015, Annals of Surgical Oncology.

[9]  Jeffrey E. Lee,et al.  Active Surveillance for Adverse Events Within 90 Days: The Standard for Reporting Surgical Outcomes After Pancreatectomy , 2015, Annals of Surgical Oncology.

[10]  B. Erickson,et al.  Defining the Role of Adjuvant External Beam Radiotherapy on Resected Adenocarcinoma of the Ampulla of Vater , 2014, Journal of Gastrointestinal Surgery.

[11]  J. Vauthey,et al.  Return to intended oncologic treatment (RIOT): A novel metric for evaluating the quality of oncosurgical therapy for malignancy , 2014, Journal of surgical oncology.

[12]  W. Regine,et al.  Adjuvant chemoradiation for pancreatic cancer: what does the evidence tell us? , 2014, Journal of gastrointestinal oncology.

[13]  C. Pilarsky,et al.  Gene Expression Profiling of Ampullary Carcinomas Classifies Ampullary Carcinomas into Biliary-Like and Intestinal-Like Subtypes That Are Prognostic of Outcome , 2013, PloS one.

[14]  O. Clausen,et al.  Intestinal-type and Pancreatobiliary-type Adenocarcinomas: How Does Ampullary Carcinoma Differ from Other Periampullary Malignancies? , 2013, Annals of Surgical Oncology.

[15]  Jeffrey E. Lee,et al.  Retroperitoneal dissection in patients with borderline resectable pancreatic cancer: operative principles and techniques. , 2012, Journal of the American College of Surgeons.

[16]  M. Büchler,et al.  Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial. , 2012, JAMA.

[17]  Jeffrey E. Lee,et al.  Histologic grading of the extent of residual carcinoma following neoadjuvant chemoradiation in pancreatic ductal adenocarcinoma , 2012, Cancer.

[18]  Jeffrey E. Lee,et al.  Defined Clinical Classifications Are Associated with Outcome of Patients with Anatomically Resectable Pancreatic Adenocarcinoma Treated with Neoadjuvant Therapy , 2012, Annals of Surgical Oncology.

[19]  J. Cameron,et al.  Evaluation of adjuvant chemoradiation therapy for ampullary adenocarcinoma: the Johns Hopkins Hospital - Mayo Clinic collaborative study , 2011, Radiation oncology.

[20]  M. Bloomston,et al.  Predictors of Survival in Periampullary Cancers Following Pancreaticoduodenectomy , 2010, Annals of Surgical Oncology.

[21]  J. Cameron,et al.  Adjuvant Chemoradiation for Pancreatic Adenocarcinoma: The Johns Hopkins Hospital—Mayo Clinic Collaborative Study , 2010, Annals of Surgical Oncology.

[22]  Jin‐Young Jang,et al.  Role of adjuvant chemoradiotherapy for ampulla of Vater cancer. , 2009, International journal of radiation oncology, biology, physics.

[23]  Dong Wook Choi,et al.  Prognostic Factors and Adjuvant Chemoradiation Therapy After Pancreaticoduodenectomy for Pancreatic Adenocarcinoma , 2009, Journal of Gastrointestinal Surgery.

[24]  L. Way,et al.  Tumors of the ampulla of vater: histopathologic classification and predictors of survival. , 2008, Journal of the American College of Surgeons.

[25]  C. Ko,et al.  Survival After Resection of Ampullary Carcinoma: A National Population-Based Study , 2008, Annals of Surgical Oncology.

[26]  Douglas B. Evans,et al.  Development of an Integrated Biospecimen Bank and Multidisciplinary Clinical Database For Pancreatic Cancer , 2008, Annals of Surgical Oncology.

[27]  W. Hop,et al.  Long-term Survival and Metastatic Pattern of Pancreatic and Periampullary Cancer After Adjuvant Chemoradiation or Observation: Long-term Results of EORTC Trial 40891 , 2007, Annals of surgery.

[28]  Y. Shan,et al.  Predictors for Patterns of Failure after Pancreaticoduodenectomy in Ampullary Cancer , 2006, Annals of Surgical Oncology.

[29]  J. Donohue,et al.  Adjuvant therapy for ampullary carcinomas: the Mayo Clinic experience. , 2006, International journal of radiation oncology, biology, physics.

[30]  J. Neoptolemos,et al.  Postoperative pancreatic fistula: an international study group (ISGPF) definition. , 2005, Surgery.

[31]  N. Demartines,et al.  Classification of Surgical Complications: A New Proposal With Evaluation in a Cohort of 6336 Patients and Results of a Survey , 2004, Annals of Surgery.

[32]  Edward L Spitznagel,et al.  Prognostic importance of comorbidity in a hospital-based cancer registry. , 2004, JAMA.

[33]  E. Rosato,et al.  Outcome of pancreaticoduodenectomy and impact of adjuvant therapy for ampullary carcinomas. , 2000, International journal of radiation oncology, biology, physics.

[34]  J. Jeekel,et al.  Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. , 1999, Annals of surgery.

[35]  A. Pietrabissa,et al.  Experience with 647 Consecutive Tumors of the Duodenum, Ampulla, Head of the Pancreas, and Distal Common Bile Duct , 1989, Annals of surgery.

[36]  Eric A. Swanson,et al.  Association of Histopathologic Phenotype of Periampullary Adenocarcinomas With Survival , 2017, JAMA surgery.

[37]  Jeffrey E. Lee,et al.  Preoperative Therapy and Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma: a 25-Year Single-Institution Experience , 2016, Journal of Gastrointestinal Surgery.

[38]  C. Willett,et al.  Carcinoma of the Ampulla of Vater: Patterns of Failure Following Resection and Benefit of Chemoradiotherapy , 2012, Annals of Surgical Oncology.

[39]  T. Eberlein.  Adjuvant Chemotherapy With Gemcitabine vs Observation in Patients Undergoing Curative-Intent Resection of Pancreatic Cancer: A Randomized Controlled Trial , 2008 .

[40]  L. Koniaris,et al.  How Many Lymph Nodes Properly Stage a Periampullary Malignancy? , 2007, Journal of Gastrointestinal Surgery.